Subsets from PBMCs were identified and the expression of the activation marker CD69 analyzed by flow cytometry. Mean CD69 expression at 3 mg/kg or PBS control.

Antibody, or TAC-003, anti-Nectin4 antibody, or TAC-003, anti-Nectin4 antibody.

Fig. 4: TAC-003 Monotherapy Demonstrates Improved Efficacy Over Nectin4 ADC

Fig. 5: mTAC-003 Monotherapy Shows Potent Dose Dependent Efficacy and Unleashes Anti-Tumor Immunological Memory

Fig. 6: mTAC-003 Monotherapy Shows Potent Dose Dependent Efficacy and Unleashes Anti-Tumor Immunological Memory

Experimental Results

Fig. 2: TAC-003 Elicits Activation of Innate and Adaptive Immunity

Fig. 3: TAC-003 Triggers Myeloid Cell Pro-inflammatory Differentiation, Activation and Potentiates Phagocytosis

Summary and Conclusions

TAC-003 was well tolerated following repeated intravenous injections in cynomolgus monkeys, as assessed by clinical observations, body weights, food consumption, hematology, serum chemistry and hemopatology.

TAC-003 is a high-affinity and Nectin4-specific, species cross-reactive, fully human antibody conjugated to optimized TLR9 agonist.

Robust immune activation and dependent activation of immune cells via FoR7 and TLR9 engagement elicits pro-inflammatory cytokine production, up-regulation of co-stimulatory molecules, enhanced APC phenotype, phagocytosis of cancer cells and triggering of adaptive immunity.

Differential MHC: Ant-tumor immunological memory and efficacy not limited to Nectin4FP tumors. TAC-003 not expected to be susceptible to same resistance mechanisms of cytotoxicity ADCC.

Potent Single Agent Efficacy Through Systemic Dosing: Nectin4-targeted localization of TAC-003 does pro-inflammatory TME and durable curative responses in models with a range of Nectin4 expression levels, including those refractory to T cell checkpoint inhibitors, with improved efficacy as compared to enfuribulin vedotin.

Increases Efficacy of T cell checkpoint inhibitors: mTAC-003 in combination with anti-PD1 antibody increases anti-tumor efficacy over single agent alone.

Clinical Candidate Ready for IND-enabling Activities: Robust preclinical package, including favorable safety profile observed in exploratory toxicity study in cynomolgus monkeys.